The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Schmitz, Susanne ^a   Adams, Roisin ^b   Walsh, Cathal ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b National Centre for Pharmacoeconomics   (Ireland)

Author keywords

Anti TNF agents; Bayesian mixed treatment comparison models; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; PLACEBO;

ARTICLE; BAYES THEOREM; COMPARATIVE STUDY; DECISION MAKING; EUROPE; EVIDENCE BASED MEDICINE; HEALTH SERVICES RESEARCH; HUMAN; MEDICAL SOCIETY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BAYES THEOREM; COMBINED MODALITY THERAPY; DECISION MAKING; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; MODELS, STATISTICAL; ORGANIZATIONAL CASE STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL;

MLCS; MLOWN;

EID: 84868292585     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-167     Document Type: Article

References (51)

1. Recent developments in meta-analysis. Sutton A, Higgins JPT, Stat Med 2008 27 625 650 10.1002/sim.2934 17590884 (Pubitemid 351278810)
2. Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades AE, Stat Med 2004 23 3105 3124 10.1002/sim.1875 15449338 (Pubitemid 39334902)
3. Spiegelhalter DJ, Abrams KR, Jonathan PM, Bayesian Approaches to Clinical Trials and Health-Care Evaluation Wiley: NewYork 2004
4. Dichotomizing continuous predictors in multiple regression: a bad idea. Royston P, Altman D, Sauerbrei W, Stat Med 2006 25 127 141 10.1002/sim.2331 16217841 (Pubitemid 43136953)
5. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Austin P, Brunner L, Stat Med 2004 23 1159 1178 10.1002/sim.1687 15057884 (Pubitemid 38477073)
6. Biased odds ratios from dichotomization of age. Chen H, Cohen P, Chen S, Stat Med 2007 26 2487 3497
7. Detecting an interaction between treatment and a continuous covariate: A comparison of two approaches. Sauerbrei W, Royston P, Zapien K, Comput Stat Data Anal 2007 51 4054 4063 10.1016/j.csda.2006.12.041 (Pubitemid 46509541)
8. Odd odds interactions introduced through dichotomisation of continuous outcomes. Breitling L, Brenner H, J Epidemiol Community Health 2010 64 300 303 10.1136/jech.2009.089458 19692723
9. Dichotomizing continuous variables in statistical analysis: a practice to avoid. Dawson N, Weiss R, Med Decision Making 2012 32 225 226 10.1177/0272989X12437605
10. Measurement in clinical trials: A neglected issue for statisticians? Senn S, Julious S, Stat Med 2009 28 3189 3209 10.1002/sim.3603 19455540
11. Sample sizes for randomized trials measuring quality of life in cancer patients. Julious S, George S, Machin D, Stephens R, Qual Life Res 1997 6 109 117 9161110 (Pubitemid 27207275)
12. Framework for describing and classifying decision-making systems using technology asesessment to determine the reimbursement of health technologies (fourth hurdle systems). Hutton J, McGrath C, Frybourg J, Tremblay M, Bramley-Harker E, Henshall C, Int J Technol Assess Health Care 2006 22 10 18 16673675 (Pubitemid 43376234)
13. Rheumatoid arthritis. Klareskog L, Catrina A, Paget S, The Lancet 2009 979 659 672
14. Bayesian methods in meta-analysis and evidence synthesis. Sutton A, Abrams KR, Stat Methods Med Res 2001 10 277 303 10.1191/096228001678227794 11491414 (Pubitemid 32691157)
15. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Nixon R, Bansback N, Brennan A, Stat Med 2007 26 1237 1254 10.1002/sim.2624 16900557 (Pubitemid 46380839)
16. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Jansen J, Crawford B, Bergman G, Stam W, Value in Health 2008 11 956 964 10.1111/j.1524-4733.2008.00347.x 18489499
17. American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Saag K, Teng G, Patkar N, Anuntiyo J, Finney C, Curtis J, Paulus H, Mudano A, Piso M, Outman R, Allison J, Suarez Almazor M, Bridges A, Chatham W, Hochberg M, Maclea C, Mikuls T, Moreland L, O'Dell J, Turkiewicz A, Furst D, Elkins-Melton M, Arthritis & Rheumatism 2008 59 762 784 10.1002/art.23721 23418544 (Pubitemid 351847559)
18. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Felson D, Anderson J, Boers M, Combarier C, Furst D, Goldsmith C, Katz L, Lightfoot R, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams H, Wolfe F, Kieszak S, Arthritis & Rheumatism 1995 38 727 735 10.1002/art.1780380602 23418544
19. Clinical outcome measures in rheumatoid arthritis. Van Riel P, van Gelstel A, Ann Rheumatic Diseases 2000 59 128 131
20. A proposed revision to the ACR20: The hybrid measure of american college of rheumatology response. American College of Rheumatology, Arthritis & Rheumatism 2007 57 193 202 10.1002/art.22552 23418544 (Pubitemid 47164079)
21. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo M, van't Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P, Arthritis & Rheumatism 1995 38 44 48 10.1002/art.1780380107 23418544
22. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group, PLoS Medicine 2009 6 1000097 10.1371/journal.pmed.1000097 19621072
23. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Schmitz S, Adams R, Walsh C, Barry M, FitzGerald O, Ann rheumatic diseases 2012 71 225 230 10.1136/annrheumdis-2011- 200228
24. Checking consistency in mixed treatment comparison meta-analysis. Dias S, Welton N, Caldwell D, Ades A, Stat Med 2010 29 932 944 10.1002/sim.3767 20213715
25. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Bucher HC, Guyatt GH, Griffith LE, Walter SD, J Clin Epidemiol 1997 50 683 691 10.1016/S0895-4356(97)00049-8 9250266 (Pubitemid 27341818)
26. Network meta-analyis for indirect treatment comparisons. Lumley T, Stat Med 2002 21 2313 2324 10.1002/sim.1201 12210616
27. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich K, Watson K, Silman A, Symmons D The BSR Biologics Register, Rheumatology 2006 45 1558 1565 10.1093/rheumatology/kel149 16705046 (Pubitemid 44817065)
28. Bayesian random effects meta-analysis of trials with binary outcomes: methods forthe absolute risk difference and relative risk scales. Warn D, Thompson D, Spiegelhalter D, Stat Med 2002 21 1601 1623 10.1002/sim.1189 12111922 (Pubitemid 34746065)
29. Prior distributions for variance parameters in hierarchical models. Gelman A, Bayesian analysis 2006 1 133 151
30. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Lunn D, Thomas A, Best N, Spiegelhalter D, Stat Comput 2000 10 325 337 10.1023/A:1008929526011
31. Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Weinblatt M, Keystone E, Furst D, Moreland L, Weisman M, Birbara C, Teoh L, Fischkoff S, Chartash E, Arthitis & Rheumatism 2003 48 35 45 10.1002/art.10697 21386777 (Pubitemid 36091645)
32. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L, Fischkoff S, Chartash E, Arthritis & Rheumatism 2004 50 1400 1411 10.1002/art.20217 23418544 (Pubitemid 38608061)
33. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Van De Putte L, Atkins C, Malaise M, Sany J, Russell A, van Riel P, Settas L, Bijlsma J, Todesco A, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff A, Kupper H, Ann Rheumatic Diseases 2004 63 508 516 10.1136/ard.2003.013052 (Pubitemid 38530193)
34. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Miyasaka N, Modern Rheumatology 2008 18 252 262 10.1007/s10165-008-0045-0 18330677
35. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. Kim H, Lee K, Song Y, Dae-Hyun Y, Koh E, Yoo B, Luo A, APLAR J Rheumatology 2007 10 9 16 10.1111/j.1479-8077.2007.00248.x (Pubitemid 46390204)
36. Infliximab (chimeric anti-tumour necrosis factor [alpha] monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, The Lancet 1999 353 1932 1939
37. The safety of infl iximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman M, Arthritis & Rheumatism 2006 54 1075 1086 10.1002/art.21734 23418544 (Pubitemid 43672920)
38. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China. Zhang F, Hou Y, Huang F, Wu D, Bao C, Ni L, Yao C, APLAR J Rheumatology 2006 9 127 130 10.1111/j.1479-8077.2006.00186.x (Pubitemid 44057326)
39. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Schiff M, Keiserman M, Codding C, Songcharoen A, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker J, Lin C, Cornet P, Dougados M, Ann rheumatic diseases 2008 67 1096 1103 10.1136/ard.2007.080002
40. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Moreland L, Schiff M, Baumgartner A, Tindall E, Fleischmann R, Bulpitt K, Weaver A, Keystone E, Furst D, Mease P, Ruderman E, Horwitz D, Arkfeld D, Garrison L, Burge D, Blosch C, Lange M, McDonnell N, Weinblatt M, Ann Internal Med 1999 130 478 486 (Pubitemid 29135800)
41. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R, Jackson C, Lange M, Burge D, New England J Med 1999 340 253 259 10.1056/NEJM199901283400401 (Pubitemid 29063266)
42. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Keystone E, Genovese M, Klareskog L, Hsia E, Hall A, Miranda P, Pazdur J, Bae S, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman M, Ann Rheumatic Diseases 2009 68 769 289
43. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, doubleblind, placebo-controlled, dose-ranging study. Kay J, Matteson E, Dasgupta B, Nash P, Durez P, Hall A, Hsia E, Han J, Wagner C, Xu Z, Visvanathan S, Rahman M, Arthritis & Rheumatism 2008 58 964 975 10.1002/art.23383 23418544 (Pubitemid 351563997)
44. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Keystone E, Van Der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K, Arthritis & Rheumatism 2009 58 3319 3329 23418544
45. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Smolen J, Landewe R, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven R, Kavanaugh A, Schiff M, Burmester G, Strand V, Vencovsky J, van der Heijde D, Ann rheumatic diseases 2008 68 797 804
46. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Fleischmann R, Vencovsky J, Van Vollenhoven R, Borenstein D, Box J, Coteur G, Goel N, Brezinschek H, Innes A, Strand V, Ann rheumatic diseases 2009 68 805 8011 10.1136/ard.2008.099291
47. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M, Pharmacoeconomics 2010 28 477 487 10.2165/11533010- 000000000-00000 20465316
48. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. Bennette C, Vickers A, BMC Med Res Methodology 2012 12 21 10.1186/1471-2288-12-21
49. Meta-analyses of screening and diagnostic tests. Hasselblad V, Hedges L, Quant Methods Psychology 1995 117 167 178
50. Selecting the best scale for measuring treatment effect in a network meta-analysis: a case study in childhood nocturnal enuresis. Caldwell D, Welton N, Dias S, Ades A, Res Synth Methods 2012 3 126 141 10.1002/jrsm.1040
51. Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. O'Rourke K, Walsh C, Hutchinson M, J Neurology 2007 254 1547 1554 10.1007/s00415-007-0584-x (Pubitemid 350159898)